TW0001795003
TW0001795003
LOTUS PHARMACEUTICAL CO
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 48.02B EUR | 49.68B EUR | 53.7B EUR | 73.42B EUR |
Enterprise Value | 100.8B EUR | 93.16B EUR | 95.49B EUR | 113.16B EUR |
Valuation Multiples | ||||
Trailing P/E | 12.69x | 13.19x | 13.94x | 22.35x |
Forward P/E | 7.59x | -- | -- | -- |
Price to Sales | 1.69x | 1.74x | 2.2x | 4.65x |
Price to Book | 2x | 2.04x | 2.23x | 3.09x |
EV/Revenue | 3.54x | 3.27x | 3.91x | 7.17x |
EV/EBITDA | 10.96x | 9.32x | 11.26x | 19.16x |
Price to FCF (P/FCF) | -- | 151.55x | 53.18x | 32.35x |
EV/FCF | -- | 284.16x | 94.55x | 49.86x |
FCF Yield | -0.12% | 0.66% | 1.88% | 3.09% |